Biogen to cut 11 percent of staff, cancel some drug programs; stock jumps

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Biogen to cut 11 percent of staff, cancel some drug programs; stock jumps

Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results

October 21, 2015 1:42 PM EDT

Leerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported a 3Q beat on all top and bottom line levels. 3Q sales of 2.78 bn. vs. consensus estimates of $2.6B, 3Q non-GAAP EPS of 4.48 vs.... More

Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat

October 21, 2015 1:36 PM EDT

Cowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported strong Q3 non-GAAP EPS of $4.48 vs. consensus of $3.84E, on revenue of $2.8B.

Analyst Eric Schmidt commented, "BIIB reported Q3 revenue and earnings well above... More

RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 Results

October 21, 2015 9:22 AM EDT

RBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $450. Earlier Biogen reported Q3 results including a corporate restructuring and headcount reduction. In the view of analyst Michael J. Yee, this was relative good news against very low... More